Nevertheless, the molecular mechanisms underlying the contradictory impact between this approach and the treatment of metabolic diseases with FXR agonists remain ambiguous, and the correlation between hepatic and intestinal FXR has not been firmly established. Here, NR1H4 is linked to metabolic disease.